Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS
· Delayed Price · Currency is USD
0.0735
+0.0014 (2.00%)
Jul 2, 2025, 2:41 PM EDT
Provectus Biopharmaceuticals Employees
Provectus Biopharmaceuticals had 6 employees as of December 31, 2024. The number of employees increased by 2 or 50.00% compared to the previous year.
Employees
6
Change (1Y)
2
Growth (1Y)
50.00%
Revenue / Employee
$109,616
Profits / Employee
-$899,701
Market Cap
31.10M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Elite Pharmaceuticals | 64 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
American Oncology Network | 1,914 |
Northwest Biotherapeutics | 25 |
CytoDyn | 9 |
Silence Therapeutics | 116 |
Provectus Biopharmaceuticals News
- 6 days ago - Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - GlobeNewsWire
- 23 days ago - Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 6 months ago - Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs - GlobeNewsWire
- 8 months ago - Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 8 months ago - Provectus Biopharmaceuticals GAAP EPS of $0.00, revenue of $0.11M - Seeking Alpha
- 9 months ago - Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call - GlobeNewsWire
- 1 year ago - Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines - GlobeNewsWire
- 1 year ago - Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting - GlobeNewsWire